Our results suggest that SIRT1 upregulation may promote the progression of leukemia by enhancing NHEJ and suppressing p53 and FOXO1 activity, and that targeting SIRT1 is a novel anticancer therapeutic strategy for treating leukemia (Figure 7). This evidence concerns the gene FOXO1 and leukemia.